China SXT Pharmaceuticals, Inc.
SXTC · NASDAQ
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.04 | 0.03 | -0.18 |
| FCF Yield | -233.39% | -16.80% | -1.00% | 0.44% |
| EV / EBITDA | 6.26 | -0.89 | -0.29 | -6.55 |
| Quality | ||||
| ROIC | -16.32% | -15.17% | -30.40% | -29.80% |
| Gross Margin | 21.11% | 28.73% | 21.62% | 48.10% |
| Cash Conversion Ratio | 0.71 | 0.62 | 0.01 | -0.05 |
| Growth | ||||
| Revenue 3-Year CAGR | -4.06% | -9.51% | -25.55% | -20.41% |
| Free Cash Flow Growth | -21.30% | -1,177.80% | -173.59% | 114.60% |
| Safety | ||||
| Net Debt / EBITDA | 6.65 | 4.01 | 2.61 | 2.67 |
| Interest Coverage | -4.14 | -4.62 | -11.76 | -141.43 |
| Efficiency | ||||
| Inventory Turnover | 1.66 | 1.70 | 2.91 | 1.33 |
| Cash Conversion Cycle | 310.63 | 130.09 | 48.96 | 649.44 |